SCHEMBL13061024

SCHEMBL13061024

Cc1cccc(CN(Cc2ccccc2)C(C)CN(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.44
ALDH1A1 P00352 2/20 0.43
TSHR P16473 1/20 0.43
SLC6A2 P23975 3/20 0.42
SLC6A4 P31645 3/20 0.42
SLC6A3 Q01959 3/20 0.42
HTR2A P28223 2/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
ADRA1A P35348 1/20 0.42
OPRK1 P41145 1/20 0.42
KCNH2 Q12809 1/20 0.42
TAS2R14 Q9NYV8 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41
PTGES O14684 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
NR3C1 P04150 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005605 0.84 SLC6A2 (0.45) TAAR1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL13060681 0.80 TAAR1 (0.43) TAAR1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL13061096 0.79 TAS2R14 (0.40) TAAR1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL12772089 0.75 TAS2R14 (0.50) TAAR1ALDH1A1TSHRTAS2R14CYP2D6
SCHEMBL24968789 0.74 SLC6A2 (0.52) TAAR1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL12857 0.74 ALDH1A1 (0.56) TAAR1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL4970861 0.73 SIGMAR1 (0.49) ALDH1A1TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL10039143 0.73 CALM1 (0.64) TAAR1ALDH1A1TSHRSLC6A2SLC6A4
SCHEMBL7048153 0.72 TAS2R14 (0.51) TAAR1ALDH1A1TSHRTAS2R14CYP2D6
SCHEMBL14024632 0.72 SLC6A2 (0.46) TAAR1ALDH1A1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed